The manufacturer of active pharmaceutical ingredients Euroapi EAPI.PA jumped more than 16% on Thursday morning on the Paris Stock Exchange after announcing that it had won a contract worth 130 million to 150 million euros with a company of animal health.
At 08:25 GMT, the stock advanced 4.3% to 3.39 euros after reaching a high of 3.79 euros.
Euroapi, a former subsidiary of Sanofi SASY.PA listed since May 2022, has signed a contract for the supply of a veterinary product for five years, over the period 2025-2029, without specifying to which company.
JPMorgan analysts estimate that this contract will allow the group to reach an annual turnover of 28 million euros, or 3% above the consensus for the period 2025-29.
Basic earnings before interest, taxes, depreciation and amortization (EBITDA) could also reach 5.6 million euros, an increase of 4% to 6% compared to the consensus 2025-28 basic EBITDA. added JPMorgan.
Euroapi has had a turbulent stock market run so far, marked by multiple profit warnings. The stock has fallen 72% since the IPO.
(Written by Gaëlle Sheehan, with Leo Marchandon, edited by Blandine Hénault)